Related Experiment Video
Updated: Jun 6, 2026
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
The use of a neonatal mouse model to study respiratory syncytial virus infections
Stephania A Cormier1, Dahui You, Srinivasa Honnegowda
1Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, USA. scorm1@lsuhsc.edu
Insights
Developing a Respiratory Syncytial Virus (RSV) vaccine is crucial. Neonatal mouse models offer a promising new approach to understanding RSV infection in infants and advancing vaccine development.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Respiratory Syncytial Virus (RSV) is a leading cause of infant mortality globally.
- High morbidity and mortality necessitate an effective RSV vaccine.
- Understanding host immune responses is key to RSV pathogenesis and vaccine efficacy.
Purpose of the Study:
- To review current murine models for RSV research.
- To highlight the emergence and potential of neonatal mouse models for studying RSV infection in infants.
- To bridge the gap in understanding RSV pathogenesis and vaccine development.
Main Methods:
- Review of existing literature on murine models for RSV.
- Analysis of emerging studies utilizing neonatal mouse models (neonates <7 days old).
- Comparison of traditional and novel animal models for RSV research.
Main Results:
- Neonatal mouse models show promise in replicating infant RSV infection.
- Age at initial infection is a critical factor in RSV pathogenesis studies.
- Current models provide insights into RSV disease mechanisms.
Conclusions:
- Neonatal mouse models represent a significant advancement in RSV research.
- These models are valuable for understanding infant RSV infection and informing vaccine strategies.
- Further research using neonatal models is essential for developing effective RSV vaccines.
Abstract:
Respiratory syncytial virus (RSV) infection is the most significant cause of viral death in infants worldwide. The significant morbidity and mortality associated with this disease underscores the urgent need for the development of an RSV vaccine. The development of an RSV vaccine has been hampered by our limited understanding of the human host immune system, which plays a significant role in RSV pathogenesis, susceptibility and vaccine efficacy. As a result, animal models have been developed to better understand the mechanisms by which RSV causes disease. Within the past few years, a revolutionary variation on these animal models has emerged--age at time of initial infection--and early studies in neonatal mice (aged <7 days at time of initial infection) indicate the validity of this model to understand RSV infection in infants. This article reviews available information on current murine and emerging neonatal mouse RSV models.
